Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Sang Youn Hwang"'
Publikováno v:
Liver Cancer, Pp 1-10 (2023)
Background: Immune checkpoint inhibitor (ICI)-based therapy such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab became mainstream first-line systemic treatment in advanced hepatocellular carcinoma (HCC) patients since remarkably sup
Externí odkaz:
https://doaj.org/article/efe0942ec76744adaa84dc30f6067185
Publikováno v:
Journal of Liver Cancer, Vol 23, Iss 1, Pp 213-218 (2023)
Recently, the efficacy of immuno-oncologic agents for advanced hepatocellular carcinoma (HCC) has been proven in several trials. In particular, atezolizumab with bevacizumab (AteBeva), as a first-line therapy for advanced HCC, has shown tremendous ad
Externí odkaz:
https://doaj.org/article/dad9d12b23b44b7393ec566d6f8e689a
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16805 (2023)
In patients with portal hypertension, there are many complications including cardiovascular abnormalities, hepatorenal syndrome, ascites, variceal bleeding, and hepatic encephalopathy. The underlying mechanisms are not yet completely clarified. It is
Externí odkaz:
https://doaj.org/article/7f49951d9e32482c80688eded94d1a71
Publikováno v:
Journal of Liver Cancer, Vol 21, Iss 2, Pp 177-180 (2021)
Sorafenib is the oldest first line systemic treatment in patients with advanced hepatocellular carcinoma (HCC) and has been used exclusively for nearly 10 years. The superiority of administering a combination of atezolizumab plus bevacizumab (AteBeva
Externí odkaz:
https://doaj.org/article/cc09564e013f47eb8fef4cdf9879d8d3
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1895 (2023)
Cirrhotic cardiomyopathy is a syndrome of blunted cardiac systolic and diastolic function in patients with cirrhosis. However, the mechanisms remain incompletely known. Since contractility and relaxation depend on cardiomyocyte calcium transients, an
Externí odkaz:
https://doaj.org/article/b56c45d5be8b4ccca1759e2d8b52bd37
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 2, Pp 3323-3334 (2015)
Chronic intermittent hypoxia, a characteristic of obstructive sleep apnea (OSA), is associated with the progression of simple hepatic steatosis to necroinflammatory hepatitis. We determined whether inhibition of a hypoxia-induced signaling pathway co
Externí odkaz:
https://doaj.org/article/cd72f2f8ef9d474683f6f446b9c77810
Publikováno v:
Journal of Liver Cancer. 21:177-180
Sorafenib is the oldest first line systemic treatment in patients with advanced hepatocellularcarcinoma (HCC) and has been used exclusively for nearly 10 years. The superiority ofadministering a combination of atezolizumab plus bevacizumab (AteBeva)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c9a17cb68167879af5405c45f4b518f
https://doi.org/10.17998/jlc.2021.09.10
https://doi.org/10.17998/jlc.2021.09.10
Autor:
Meiling Zhang, Seung-Hyun Jun, Youngho Wee, Han Sol Kim, Ee Taek Hwang, Jongmin Shim, Sang Youn Hwang, Jinwoo Lee, Jungbae Kim
Publikováno v:
International journal of biological macromolecules. 222
Lipases catalyze a wide range of industrially important reactions, including the transesterification of triglycerides with alcohols for biodiesel production, and the stabilization of lipases are critical to achieve their recycled uses. Here, nanoscal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ad54791db47703485499692a5b87e1
https://pubmed.ncbi.nlm.nih.gov/36216105
https://pubmed.ncbi.nlm.nih.gov/36216105
Autor:
Eun Sun Jang, Sang Youn Hwang, Do Young Kim, Yeon Seok Seo, Young Mi Hong, Ji Hoon Kim, Jeong Hoon Lee, Young-Sun Lee, Young Kul Jung, Jae Young Jang, Hyun Woong Lee, Moon Young Kim, Sung Bum Cho, Hyung Joon Kim, Hyung Joon Yim, Ki Tae Yoon, Byoung Kuk Jang
Publikováno v:
European Journal of Cancer. 140:19-27
Background: Hand-foot skin reaction (HFSR) is the most common adverse event during sorafenib treatment, which is the main reason for dose de-escalation or discontinuation of sorafenib in hepatocellular carcinoma (HCC) patients. Here, we aimed to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e6f4e4c45696d5e913f756a2d78c3d
https://doi.org/10.1016/j.ejca.2020.09.012
https://doi.org/10.1016/j.ejca.2020.09.012
Autor:
Sang Youn Hwang, Jung Woo Im, Kyung-Su Kim, Wan Jeon, Cheol-Won Choi, Seon-Mi Lee, Ki Jeong Jeon
Publikováno v:
Journal of Liver Cancer. 19:74-78
Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f791f3318c765069ec38af6e767a6a54
https://doi.org/10.17998/jlc.19.1.74
https://doi.org/10.17998/jlc.19.1.74